Dentsply Sirona Earnings Fall To $0.29 A Share Despite $39 Million Accounting Benefit

Dental sales weakened across all three businesses, while Wellspect posted record quarterly sales and free cash flow fell to zero.

Share
Dentsply Sirona Earnings Fall To $0.29 A Share Despite $39 Million Accounting Benefit

Dentsply Sirona, which makes dental equipment, implants, clear aligners and consumables, reported third-quarter adjusted earnings of $0.29 a share Thursday, down from $0.42 a year earlier despite a $39 million inventory-accounting benefit. Sales fell to $836 million from $904 million, down 7.6% as reported and 7.0% excluding currency changes, according to results furnished with its SEC filing.

An Earnings Lift That Won’t Repeat

The $39 million benefit came from changing the estimate used to remove unrealized profit from inventory. The revision captured a cumulative effect, reduced the reported net loss and added approximately $30 million to adjusted net income. The company said it does not expect equivalent benefits in future periods.

Even with that help, adjusted net income was $59 million, versus $84 million a year earlier. Adjusted earnings per share declined 29.4%. Adjusted earnings before interest, taxes, depreciation and amortization fell 13.3% to $146 million, and the margin on that measure slipped to 17.3% from 18.4%.

Under standard accounting, the loss attributable to shareholders was $2 million, or $0.01 a share, compared with $427 million, or $2.14 a share, a year earlier. Goodwill and intangible-asset impairment charges were $3 million, versus $262 million in the prior-year quarter. Gross margin rose to 52.9% from 48.8%; the adjusted gross margin was 54.5%, versus 52.6%.

Wellspect Grows, Dental Businesses Shrink

Wellspect Healthcare delivered record quarterly sales of $92 million, up from $83 million. Growth was 10.1% as reported and 11.0% excluding currency movements. The company also launched the Surity Urinary Management System, completing its U.S. Surity portfolio.

The dental businesses moved the other way:

  • Connected Technology Solutions generated $230 million, versus $259 million, down 11.0% as reported and 10.1% excluding currency changes.
  • Essential Dental Solutions generated $343 million, versus $357 million, down 4.0% as reported and 3.6% excluding currency changes.
  • Orthodontic and Implant Solutions generated $171 million, versus $205 million, down 16.6% as reported and 16.2% excluding currency changes.

Dentsply Sirona serves dentists and dental laboratories with products ranging from imaging systems and intraoral scanners to implants and clear aligners. Wellspect supplies continence-care products for urological and bowel management. About two-thirds of the company’s dental consumable, technology and equipment products reach customers through third-party distributors.

Dan Scavilla, president and CEO of Dentsply Sirona, pointed to progress in implants and endodontics and an expanded U.S. dealer network. Describing the company’s return-to-growth plan, he said, “our focus is now on execution,” with sales-force, clinical-education and innovation efforts central to that work.

Zero Free Cash Flow, Continued Buybacks

Third-quarter free cash flow—cash left after capital spending—was zero, versus $40 million a year earlier. Operating cash flow fell to $32 million from $79 million, primarily because of unfavorable working-capital changes, while capital spending was $32 million.

The company nevertheless bought back 1.2 million shares for approximately $13 million during the quarter. Repurchases totaled $25 million for the first nine months of 2026. Cash and equivalents stood at $195 million on September 30, compared with $326 million at the end of 2025.

Dentsply Sirona’s updated full-year outlook calls for approximately $3.5 billion in sales and adjusted earnings of $1.20 to $1.30 a share, excluding a $0.17 one-time tariff-refund benefit.

Sources

More on Dentsply Sirona

All Dentsply Sirona (XRAY) coverage →